Fosanis, a Berlin, Germany-based digital health company which develops Mika, a prescription DTx for all oncological indications, closed a series A funding round of more than €10m.
The round was led by Debiopharm Innovation Fund, with participation from, Ananda Impact Ventures, and Ship2B Ventures and Equity Pitcher.
The company intend stop use the funds to expand into international terrain.
Founded in 2017 by Dr Gandolf Finke and Dr Jan Simon Raue, Fosanis has developed the AI-powered DTx Mika in collaboration with oncological research institutions and cancer centres such as the University of Leipzig Medical Center and Charité Berlin. Mika is a personalised digital therapeutic (DTx) platform in oncology, which delivers evidence-based digital interventions with a view to supporting cancer patients in coping with the challenges of the disease and treatment process. Daily check-ups – so-called ePROs = electronic patient-reported outcomes – allow continuous tracking of distress levels and symptoms, while a personalised coaching programme provides scientifically validated multi-media elements and psychooncological interventions. These include over 800 rigorously validated articles, videos and coping skills training courses – ranging from nutrition recommendations to physical exercise training and mindfulness coaching.
Fosanis employs more than 40 people.